AbbVie Story

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:3em;'>ABB</div>
ABBV -- USA Stock  

USD 86.23  0.32  0.37%

AbbVie Cash and Equivalents Turnover is fairly stable at the moment as compared to the past year. AbbVie reported Cash and Equivalents Turnover of 1.41 in 2019. Return on Investment is likely to grow to 30.15 in 2020, whereas Revenue Per Employee is likely to drop slightly above 948.3 K in 2020. AbbVie Inc is scheduled to announce its earnings today. The next earnings report is expected on the 6th of November 2020. Is healthcare space attracting new sophisticated investors, let's check if AbbVie Inc is sending any bullish signals. We will evaluate why we are still confident in anticipation of a recovery. We currently estimate AbbVie as undervalued. The real value is approaching 107.11 per share.
Published over a month ago
View all stories for AbbVie | View All Stories
How stable are AbbVie (NYSE:ABBV) forward indicators given the latest climb?
Macroaxis provides advice on AbbVie Inc to complement and cross-verify current analyst consensus on AbbVie Inc. Our investment recommendation engine determines the company's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon. This firm dividends can provide a clue to the current value of the stock. AbbVie one year expected dividend income is about $3.28 per share.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include AbbVie income statement, its balance sheet, and the statement of cash flows. Potential AbbVie investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although AbbVie investors may use each financial statement separately, they are all related. The changes in AbbVie's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AbbVie's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of AbbVie fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of AbbVie performance into the future periods or doing a reasonable stock valuation. The intrinsic value of AbbVie shares is the value that is considered the true value of the share. If the intrinsic value AbbVie is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares AbbVie. Please read more on our fundamental analysis page.

What is AbbVie Asset Breakdown?

AbbVie Inc reports assets on its Balance Sheet. It represents the amount of AbbVie resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect AbbVie volatility, please check the breakdown of all its fundamentals

Are AbbVie Earnings Expected to grow?

The future earnings power of AbbVie involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of AbbVie factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. AbbVie stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of AbbVie expected earnings.

And What about dividends?

A dividend is the distribution of a portion of AbbVie earnings, decided and managed by the company's board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. AbbVie dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment. AbbVie one year expected dividend income is about $3.28 per share.
Payment of Dividends and Other Cash Distributions is likely to drop to about (6.9 B) in 2020. Dividend Yield is likely to drop to 0.0449 in 2020.
Last ReportedProjected for 2020
Payment of Dividends and Other Cash Distributions-6.4 B-6.9 B
Dividend Yield 0.048  0.0449 
Dividends per Basic Common Share 4.28  3.74 
Investing in dividend-paying stocks, such as AbbVie Inc is one of the few strategies that are good for long-term investment. Ex-dividend dates are significant because investors in AbbVie must own a stock before its ex-dividend date to receive its next dividend. This type of analysis is very useful when you want to generate a past dividend schedule and payout information for AbbVie. Then that information in the form of graph and calendar can be used to fully explain how Du Pont dividends can provide a real clue to its valuation.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for AbbVie, but it might be worth checking our own buy vs. sell analysis

AbbVie Gross Profit

AbbVie Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing AbbVie previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show AbbVie Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Breaking down the case for AbbVie

There are few distinct groups of AbbVie stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of AbbVie is distributed among investors.

Ownership Allocation

AbbVie holds a total of one billion seven hundred sixty million outstanding shares. The majority of AbbVie Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AbbVie Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AbbVie. Please pay attention to any change in the institutional holdings of AbbVie Inc as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Retail Investors
Retail Investors23.13
 2017 2018 2019 2020 (projected)
Consolidated Income5.31 B5.69 B7.88 B6.96 B
Direct Expenses7.04 B7.72 B7.44 B6.23 B

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AbbVie has an asset utilization ratio of 64.2 percent. This indicates that the company is making $0.64 for each dollar of assets. An increasing asset utilization means that AbbVie Inc is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
53.4 B
Assets Non Current
36.9 B
31.6 B
Current Assets53.43 Billion43.45
Assets Non Current36.92 Billion30.02
Goodwill31.61 Billion25.71
Tax Assets1.01 Billion0.82

AbbVie will most likely finish below $98 in 60 days

Latest Skewness is up to 0.09. Price may slide again. AbbVie Inc has relatively low volatility with skewness of 0.09 and kurtosis of 1.09. However, we advise all investors to independently investigate AbbVie Inc to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

While some companies under the drug manufacturers?general industry are still a bit expensive, AbbVie may offer a potential longer-term growth to sophisticated investors. The bottom line, as of the 31st of July 2020, we see that AbbVie slowly supersedes the market. The venture is undervalued with below average chance of distress within the next 24 months. Our current 30 days Buy-Hold-Sell recommendation on the venture is Strong Buy.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of AbbVie Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to